A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration Clinical Trial

Official title:
A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety and pharmacokinetics of KPS-0373 in SCD patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01970098
Study type	Interventional
Source	Kissei Pharmaceutical Co., Ltd.
Contact
Status	Completed
Phase	Phase 3
Start date	October 9, 2013
Completion date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02889302` - An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
Completed	`NCT04107740` - C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration	Phase 4
Completed	`NCT01004016` - A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 2
Completed	`NCT00863538` - Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 2
Completed	`NCT01970137` - A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
Completed	`NCT01970111` - An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
Completed	`NCT01970124` - A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3